At the core of this study is an innovative online tool developed by the Northwestern scientists. This calculator estimates a person’s heart age based on various cardiovascular disease risk factors, such as blood pressure, cholesterol levels, smoking status, and the presence of diabetes. It aims to transform the way risk is presented, making it more relatable and understandable for patients. Although the calculator serves as a valuable resource, the research team emphasizes that it is meant to complement, not replace, professional medical advice.

Scheduled for publication on July 30 in the prestigious journal JAMA Cardiology, the study redefines the way heart disease risk traditionally has been understood. Clinicians often present cardiovascular risk in percentage terms, such as stating that a person has an 8% chance of experiencing a heart-related incident within the next decade. However, the new calculator takes this statistical risk and translates it into an age representation, Revolutionizing the dialogue surrounding heart health.

Dr. Sadiya Khan, the Magerstadt professor of cardiovascular epidemiology at Northwestern University Feinberg School of Medicine, serves as the senior author of this research. She was instrumental in the creation of the PREVENT equations that form the basis of the heart age calculator. Dr. Khan hopes this tool will improve discussions about heart disease risk and guide treatment decisions to prevent significant health events like heart attacks, strokes, or heart failures from occurring altogether.

To assess the efficiency of the heart age calculator, Dr. Khan and her research team conducted an extensive evaluation involving over 14,000 adults ranging from ages 30 to 79. These individuals participated in the National Health and Nutrition Examination Survey from 2011 to 2020, specifically selected due to their lack of prior cardiovascular disease. The data gathered provided crucial insights into the heart age disparities prevalent among the population.

The findings revealed that, on average, women possessed a heart age of 55.4 years, significantly older than their average chronological age of 51.3 years. More alarmingly, men exhibited an even more substantial gap, with an average heart age of 56.7 years, raising important questions about the cardiovascular health of the male population. This indicates a hidden risk that may be overlooked, further illustrating the necessity for preventive measures and health interventions.

Among various demographic groups, individuals with a high school education or less demonstrated alarming statistics. Nearly one-third of this population group exhibited a heart age exceeding ten years beyond their actual age. This disparity highlights the intersection of education, socioeconomic status, and cardiovascular health, emphasizing the urgent need for targeted public health messaging to reach these communities effectively.

The racial disparities in heart age were particularly profound. The research observed that Black men had a heart age an average of 8.5 years older than their actual age, while Hispanic men followed closely behind with an age gap of 7.9 years. In comparison, Asian and white men had smaller discrepancies at 6.7 years and 6.4 years respectively. The trends were also prominent among women, with Black women’s heart age exceeding their actual age by an average of 6.2 years and Hispanic women showing a 4.8-year gap.

Heart disease remains the leading cause of mortality in the United States, a statistic that has persisted despite significant advancements in public health measures aimed at reducing cardiovascular incidents. One factor contributing to this enduring epidemic is that many individuals who would greatly benefit from preventive care do not receive it in a timely manner. Dr. Khan emphasizes that an alarming number of people who should be prescribed medications to mitigate their heart disease risk remain untreated, marking a critical area for intervention.

This newly introduced heart age calculator is designed to enhance awareness and foster dialogue surrounding preventive care options. By portraying cardiovascular risk in a more relatable manner, Dr. Khan advocates for a proactive approach to heart health. Particularly for younger adults, who often underestimate their risk for heart disease, this tool has profound implications. Early identification of cardiovascular risk can lead to effective interventions that slow down the seeming aging process of the heart.

Future research efforts will look closely at whether the heart age presentation shifts the understanding of cardiovascular risk and leads to improved health outcomes. As healthcare professionals integrate these findings and tools into clinical practice, the hope is for a cascade of benefits, ultimately reducing the incidence of heart disease.

This study, aptly titled “PREVENT Risk Age Equations and Population Distribution in US Adults,” signals a significant step toward redefining how cardiovascular health risks are communicated and addressed nationwide. It is a call to action for both patients and healthcare providers to engage in meaningful conversations about heart disease prevention.

The findings of this groundbreaking research bring to light the urgency of addressing health disparities and ensuring equitable access to preventive care. By equipping individuals with tools that enhance their understanding of cardiovascular risks, healthcare can shift from a reactive model to one that prioritizes prevention, fostering healthier communities and improved quality of life moving forward.

In summary, addressing heart disease requires a comprehensive approach that combines innovative tools, clear communication, and equitable access to healthcare. As Dr. Khan and her team continue their research, the potential for meaningful change within the realm of cardiovascular health is unmistakable.

Subject of Research: Heart Age and Cardiovascular Disease Risk
Article Title: PREVENT Risk Age Equations and Population Distribution in US Adults
News Publication Date: 30-Jul-2025
Web References: JAMA Cardiology Article
References: N/A
Image Credits: N/A

Keywords

Health and medicine, cardiology, cardiovascular disorders, epidemiology, preventive medicine, risk management, risk communication, risk reduction

Dr. Robert Rosenson, a distinguished Professor of Medicine (Cardiology) at Mount Sinai and the lead author of the study, emphasized the groundbreaking nature of their research. The analysis of the trial demonstrated that higher doses of olpasiran caused reductions in Lp(a) levels by over 95 percent in participants suffering from atherosclerotic cardiovascular disease. These formidable results, published in the prestigious journal JAMA Cardiology on February 12, 2025, signal a possible paradigm shift in how we approach cardiovascular health.

Lipoprotein(a) is particularly notorious in cardiovascular research. Considered a major facilitator in the transport of oxidized phospholipids, Lp(a) is linked to inflammation and the progression of atherosclerosis, which can lead to serious vascular complications. This trial, as it turns out, was the first to explore the relationship between oxidized phospholipids present on Lp(a) and inflammatory mediators in a clinical setting. The intricate biological dance between Lp(a) and inflammation unlocked new pathways in understanding cardiovascular disease etiology.

Olpasiran functions as a small interfering RNA, exhibiting a sophisticated mechanism to curtail Lp(a) production. By inducing degradation of apolipoprotein(a) messenger RNA—essentially the blueprint for forming Lp(a)—olpasiran effectively diminishes one of the significant players in the lipid profile of at-risk patients. This process underscores olpasiran’s potential therapeutic efficacy as a targeted intervention against cardiovascular disease, especially in those with elevated Lp(a) levels.

What makes olpasiran particularly noteworthy in clinical practice is its results from the randomized phase 2 clinical trial known as OCEAN(a)-DOSE. This trial involved 282 patients who were not only living with cardiovascular disease but had Lp(a) levels exceeding 150 nmol/L. This threshold is crucial, given that such levels have been associated with heightened risks of clotting and inflammation that can compromise heart health. The study aimed to provide a clearer picture of how olpasiran could alter these risk dynamics and contribute to novel therapeutic strategies.

The results illuminate a compelling narrative for the utility of olpasiran. Participants administered doses of 75 mg or higher every 12 weeks showcased a remarkable 95 percent reduction in Lp(a) when evaluated against a placebo group over a 36-week period. In stark contrast, the placebo cohort experienced a 3.6 percent uptick in Lp(a) levels. This disparity reinforces the potential of RNA inhibitors as transformative tools in the management of cardiovascular diseases linked to high Lp(a) levels.

Beyond decreasing Lp(a), the research team noted that olpasiran also lowered levels of oxidized phospholipids associated with apolipoprotein B—an essential lipid transport protein implicated in cardiovascular disease. However, intriguingly, the study did not observe significant effects on the secretion of proinflammatory cytokines such as interleukin-6 or C-reactive protein in comparison to those receiving the placebo. This nuanced understanding is vital, as it directs future research efforts toward elucidating the comprehensive impacts of olpasiran on not just one but multiple fronts of cardiovascular pathology.

Dr. Rosenson articulated the need for further investigations that delve into the mechanisms through which Lp(a) contributes to cardiovascular risk. By challenging existing paradigms, his team’s work sets the stage for more personalized approaches in patient selection for future trials, particularly those exploring the anti-inflammatory potential of RNA inhibitors in combating cardiovascular diseases. The scientific community’s collective actions now must leverage this foundational work to tease apart the complexities inherent in lipid-mediated atherosclerosis.

The trial’s sophisticated structure and significant outcomes echo a shifting paradigm in therapeutic development for cardiovascular ailments. The OCEAN(a)-DOSE trial was expertly orchestrated under the auspices of the TIMI Study Group and received sponsorship from Amgen, a crucial relationship that underscores the importance of collaboration between academia and industry in advancing healthcare solutions. As the medical fraternity anticipates phase 3 trials for olpasiran, hope grows for a future where innovative therapies reshape the landscape of cardiovascular disease management.

Mount Sinai’s continuous commitment to excellence in cardiology is underscored by its ranking as a leading institution for heart health, especially in light of its innovative research and clinical advancements. As healthcare systems grapple with escalating cardiovascular disease rates, findings like those from the olpasiran trial point to a crucial direction for future therapeutic protocols. Acknowledging the complexity of cardiovascular health, the insights garnered from this study lend themselves to a broader discourse on the imperative of personalized medicine in the fight against cardiovascular disease.

As the scientific community, healthcare professionals, and patients alike await the next steps, olpasiran stands as a beacon of hope in a field that urgently requires transformative approaches. This RNA inhibitor’s potential for significantly altering the risk landscape associated with Lp(a) heralds a new era of cardiovascular disease management—one where innovation meets patient-oriented care to revolutionize health outcomes globally.

Researchers, clinicians, and patients must remain vigilant as they further navigate this promising frontier in cardiovascular health, ensuring that advancements like olpasiran not only enter clinical practice but also become standard components of comprehensive care strategies aimed at reducing cardiovascular morbidity and mortality.

Subject of Research: People
Article Title: Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers
News Publication Date: 12-Feb-2025
Web References:
References:
Image Credits: Credit: Mount Sinai Health System

Keywords: Cardiovascular Health, Lipoprotein(a), RNA Inhibitor, Olpasiran, Atherosclerosis, Inflammation, Clinical Trials, Pharmacology, Personalized Medicine, Heart Disease, Oxidized Phospholipids, Apolipoprotein B.